FDA to Review “New” Migraine Drug
The FDA has accepted for review a “new” migraine drug, Trexima, that was developed by Pozen for sale by GlaxoSmithKline. Trexima is a combination of sumitriptan (Imitrex) and naproxen sodium (the ingredient in Aleve).
Hmm, could this be GSK’s desperate attempt to hold the patent (set to expire in 2009) on a drug that brings in loads of money? Patients who spend small fortunes on triptans each year would probably be willing to forego the convenience of taking one pill instead of two.